Medicenna Therapeutics (OTCMKTS:MDNAF) Releases Earnings Results, Hits Estimates

Medicenna Therapeutics (OTCMKTS:MDNAF) announced its earnings results on Thursday, June 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05), Zacks reports.

Medicenna Therapeutics Price Performance

Shares of OTCMKTS MDNAF traded down $0.03 during midday trading on Thursday, reaching $0.28. The company’s stock had a trading volume of 58,635 shares, compared to its average volume of 70,371. The stock has a 50 day simple moving average of $0.35. The company has a market cap of $25.38 million, a PE ratio of -1.72 and a beta of 1.75. Medicenna Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $1.43.

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.